RT Journal Article
SR Electronic
T1 Altered Resting State Brain Networks and Cognition in Familial Adenomatous Polyposis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.02.20224477
DO 10.1101/2020.11.02.20224477
A1 Ryan J. Cali
A1 Benjamin C. Nephew
A1 Constance M. Moore
A1 Serhiy Chumachenko
A1 Ana Cecilia Sala
A1 Beatriz Cintron
A1 Carlos Luciano
A1 Jean A. King
A1 Stephen R. Hooper
A1 Francis M. Giardiello
A1 Marcia Cruz-Correa
YR 2020
UL http://medrxiv.org/content/early/2020/11/04/2020.11.02.20224477.abstract
AB Familial Adenomatous Polyposis (FAP) is an autosomal dominant disorder caused by mutation of the APC gene presenting with numerous colorectal adenomatous polyps and a near 100% risk of colon cancer. Preliminary research findings from our group indicate that FAP patients experience significant deficits across many cognitive domains. In the current study, fMRI brain metrics in a FAP population and matched controls were used to further the mechanistic understanding of reported cognitive deficits. This research identified and characterized any possible differences in resting brain networks and associations between neural network changes and cognition from 34 participants (18 FAP patients, 16 healthy controls). Functional connectivity analysis was performed using FSL with independent component analysis (ICA) to identify functional networks. Significant differences between cases and controls were observed in 8 well-established resting state networks. With the addition of an aggregate cognitive measure as a covariate, these differences were virtually non-existent, indicating a strong correlation between cognition and brain activity at the network level. The data indicate robust and pervasive effects on functional neural network activity among FAP patients and these effects are likely involved in cognitive deficits associated with this disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding: Supported by Award Number 2U54MD007587 from the National Institute on Minority Health and Health Disparities and National Institute of Allergy and Infectious Diseases and the Investigational Fund of the University of Puerto Rico Vice Presidency for Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Participants signed informed consent (or assent for children) prior to participation in the study and were evaluated at the Puerto Rico Clinical and Translational Research Consortium at the University of Puerto Rico (UPR) Medical Sciences Campus. The research protocol was approved by the Institutional Review Board of the UPR Medical Sciences Campus.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available via the Open Science Framework.